April 30th 2024
Benjamin Tomlinson, MD, discusses the first-line approval of luspatercept and other ongoing research in low-risk MDS.
April 29th 2024
Gottfried E. Konecny, MD, discusses PRO data for mirvetuximab soravtansine derived from the phase 3 MIRASOL trial.
April 27th 2024
Sara Corvigno, MD, PhD, expands on an analysis that uncovered the CHIP variants that occurred at a higher frequency in patients with ovarian cancer post-chemotherapy.
April 26th 2024
Zeynep Eroglu, MD, discusses how findings from a phase 1/2 study of ceritinib and trametinib could help inform future research in melanoma.
Frontline amivantamab with chemotherapy has been recommended for approval by the CHMP in EGFR exon 20 insertion+ non–small cell lung cancer.
CHMP has voiced its support for the approval of fruquintinib in previously treated metastatic colorectal cancer.
Robert W. Mutter, MD, discusses personalized treatment approaches with radiation and endocrine therapy in early-stage breast cancer.
April 25th 2024
Sundar Jagannath, MBBS, discusses linvoseltamab and expands on key efficacy and safety findings from the LINKER-MM1 trial in patients with relapsed/refractory multiple myeloma.
April 24th 2024
Robert W. Mutter, MD, discusses research involving partial breast irradiation and multi-modality therapy in early-stage breast cancer.
April 23rd 2024
OBX-115 was well tolerated and produced durable antitumor responses in patients with immune checkpoint inhibitor (ICI)-resistant advanced melanoma.
April 22nd 2024
SCIB1 plus nivolumab and ipilimumab elicited responses in patients with advanced, unresectable melanoma.
The FDA has granted breakthrough therapy designation to ziftomenib for the treatment of NPM1-mutant acute myeloid leukemia.
April 20th 2024
Idalid Franco, MD, MPH, discusses the integration of immunotherapy, molecular biomarkers, and risk factors for recurrence into the endometrial cancer paradigm.
April 18th 2024
The European Medicines Agency has granted orphan drug designation to annamycin for the treatment of patients with acute myeloid leukemia.
April 17th 2024
Real-world treatment with zanubrutinib was linked to longer treatment persistence, duration, and time to discontinuation in mantle cell lymphoma.
April 15th 2024
A retrospective cohort study acalabrutinib and zanubrutinib are being increasingly adopted for the treatment of CLL/SLL in the community setting.
Ibrahim Aldoss, MD, discusses the FDA approval of ponatinib plus chemotherapy in newly diagnosed, Ph-positive acute lymphoblastic leukemia.
Glofitamab plus chemotherapy generated an overall survival improvement vs rituximab plus chemotherapy in relapsed/refractory diffuse large B-cell lymphoma.
April 12th 2024
A real-world study showed zanubrutinib was linked with fewer cardiac adverse effects vs ibrutinib and acalabrutinib in chronic lymphocytic leukemia.
Anne Favret, MD discusses the evolution of treatment with endocrine-based combination therapies in HR-positive/HER2-negative metastatic breast cancer.